Skip to Content
Event ANT Neuromeeting 2027 - Berlin starts on Jan 14, 2027, 8:00:00 AM (Europe/Berlin)
John Foxe
(30 minutes)
John Foxe
Dr. John J. Foxe
Killian J. and Caroline F. Schmitt Chair in Neuroscience Director, Ernest J. Del Monte Institute for Neuroscience Director, Golisano Intellectual & Developmental Disabilities Institute Chair, Department of Neuroscience at University of Rochester
Dr. John J. Foxe
Killian J. and Caroline F. Schmitt Chair in Neuroscience Director, Ernest J. Del Monte Institute for Neuroscience Director, Golisano Intellectual & Developmental Disabilities Institute Chair, Department of Neuroscience at University of Rochester
John J. Foxe, Ph.D., is an internationally recognized neuroscientist whose research has advanced understanding of sensory processing, attention, multisensory integration, and neurodevelopmental and psychiatric disorders. He holds the Kilian J. and Caroline F. Schmitt Chair in Neuroscience at the University of Rochester, where he serves as Professor and Chair of Neuroscience and directs both the Ernest J. Del Monte Institute for Neuroscience and the Golisano Intellectual and Developmental Disabilities Institute.

Over a career spanning more than three decades, Dr. Foxe has held prominent academic and research leadership positions, including tenured appointments at Albert Einstein College of Medicine and the City University of New York. He has authored hundreds of peer-reviewed publications, garnering over 49,000 citations and an H-index of 111. His research spans autism, schizophrenia, ADHD, and substance-use disorders, with a strong emphasis on translational neuroscience. He also serves as Editor-in-Chief of the European Journal of Neuroscience.
The development of effective therapies for neurodevelopmental disorders remains hampered by a critical translational gap between mechanistic discoveries in preclinical models and meaningful clinical outcomes. Cross-species electroencephalography (EEG) offers a powerful approach to bridging this divide, providing objective, scalable measures of neural circuit function that can be assessed using comparable paradigms in animals and humans. In this talk, I will describe our efforts to develop and validate translational EEG biomarkers across several neurodevelopmental disorders, including autism and rare genetic conditions. Drawing on convergent evidence from human studies and experimental models, I will illustrate how sensory and cognitive electrophysiological signatures can reveal conserved circuit dysfunction, track disease progression, and potentially index therapeutic response. Particular emphasis will be placed on the challenges of establishing biomarker reliability, biological relevance, and pharmacodynamic sensitivity. Ultimately, this work aims to establish a framework for advancing mechanistically grounded, trial-ready biomarkers that can accelerate therapeutic development.